This article is more than 5 years old. Information may no longer be current.
Medical center appoints chief of hematology/oncology
NewYork-Presbyterian/Columbia University Medical Center appointed Gary Schwartz, MD, as chief of the division of hematology/oncology and associate director for research at its Herbert Irving Comprehensive Cancer Center.
Schwartz will lead the expansion of clinical research and patient care at the cancer center. He also will continue his research on improving ways to treat melanoma, sarcoma, and cancers of the gastrointestinal tract.
“We are very excited to welcome Dr. Schwartz,” Stephen Emerson, MD, PhD, director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, said in a press release. “He brings an unparalleled background in translational and clinical research, including the development and testing of new anticancer drugs. Dr. Schwartz will be an invaluable asset in our research efforts, from the molecular and cellular mechanisms of cancer, through its unique behavior in different tissues, to statistical aspects of its occurrence and treatment in large populations.”
Gary Schwartz
Schwartz previously served as chief of the melanoma and sarcoma service at Memorial Sloan-Kettering Cancer Center. He also directed Memorial Sloan-Kettering’s Laboratory of New Drug Development.
“Patients will benefit greatly from Dr. Schwartz’s expertise, not only in the treatment of melanoma, sarcoma, and cancers of the gastrointestinal tract, but also a wide variety of solid tumors and hematologic malignancies, through his focus on novel agents with activity against fundamental mechanisms of cancer,” said Donald W. Landry, MD, physician-in-chief at NewYork-Presbyterian/Columbia and chair of the department of medicine at Columbia University Medical Center. “Further, he brings a keen sense of compassion and commitment to patient-centered practice, personifying all that we strive for in clinical care at NewYork-Presbyterian/Columbia.”
Schwartz has worked on several review committees for the NIH. He also is co-chair of the Alliance for Clinical Trials in Oncology’s experimental therapeutics committee.
“I am thrilled to be joining the Herbert Irving Comprehensive Cancer Center at NYP/Columbia,” Schwartz said. “As a National Cancer Institute-designated cancer center, the Herbert Irving Cancer Center has some of the premier scientists, clinicians and facilities in the country. I hope to be able to tap into the extraordinary resources and talent here to turn scientific breakthroughs into state-of-the-art cancer treatments.”